These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33402840)

  • 1. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.
    Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M;
    Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
    JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
    AlMatar M; Albarri O; Makky EA; Var I; Köksal F
    Mini Rev Med Chem; 2020; 20(18):1908-1916. PubMed ID: 32811410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol: An Overview of Its
    Yao J; Wang J; Chen M; Cai Y
    Front Med (Lausanne); 2021; 8():741940. PubMed ID: 34950677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.
    Giacobbe DR; Labate L; Russo Artimagnella C; Marelli C; Signori A; Di Pilato V; Aldieri C; Bandera A; Briano F; Cacopardo B; Calabresi A; Capra Marzani F; Carretta A; Cattelan A; Ceccarelli L; Cenderello G; Corcione S; Cortegiani A; Cultrera R; De Rosa FG; Del Bono V; Del Puente F; Fanelli C; Fava F; Francisci D; Geremia N; Graziani L; Lombardi A; Losito AR; Maida I; Marino A; Mazzitelli M; Merli M; Monardo R; Mularoni A; Oltolini C; Pallotto C; Pontali E; Raffaelli F; Rinaldi M; Ripa M; Santantonio TA; Serino FS; Spinicci M; Torti C; Trecarichi EM; Tumbarello M; Mikulska M; Giacomini M; Marchese A; Vena A; Bassetti M;
    Infect Dis Ther; 2024 Sep; 13(9):1929-1948. PubMed ID: 38995601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 14. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement.
    Cortegiani A; Ingoglia G; Ippolito M; Girardis M; Falcone M; Pea F; Pugliese F; Stefani S; Viale P; Giarratano A
    J Anesth Analg Crit Care; 2022 Jul; 2(1):34. PubMed ID: 37386663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.
    Morris CP; Bergman Y; Tekle T; Fissel JA; Tamma PD; Simner PJ
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32938734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
    Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.